HiFiBiO Therapeutics, an emerging multinational biotherapeutics company that seeks to combat diseases by mobilizing the human immune system, has raised $37.5 million in a Series B financing co-led by Sequoia China and LYFE Capital.
Existing Series A investors VI Ventures and Nest.Bio Ventures, as well as new investors Legend Star Capital and Proxima Ventures, also backed the funding round of the US-based startup that also has offices in France and China.
